A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

Inclusion Criteria:

• Participant must be greater than or equal to (>=) 18 years of age, at the time ofsigning informed consent

• Tumor must be histologically confirmed cluster of differentiation (CD)19 and/or CD20positive

• Must meet the indications for each subtype in Phase 1b as specified in protocol andPhase 2 participants must have following: Diagnosis of Large B-cell lymphoma (LBCL),Follicular large B-cell lymphoma (FLBCL), or transformation of indolent lymphoma;Received at least 2 prior lines of systemic therapy; Relapsed or refractory diseasedefined as 1 or more of the following: Stable disease or Progressive disease (PD) asbest response to most recent anti-lymphoma therapy OR disease progression orrecurrence after a partial response (PR) or complete response (CR) to most recentanti lymphoma therapy; cohort specific requirements as mentioned in protocol

• Measurable disease as defined by Lugano 2014 classification

• Eastern cooperative oncology group (ECOG) performance status of 0 to 2

Exclusion Criteria:

• History of symptomatic deep vein thrombosis or pulmonary embolism within six monthsof apheresis (line associated deep vein thrombosis is allowed)

• History of stroke, unstable angina, myocardial infarction, congestive heart failureNew York Heart Association (NYHA) Class III or IV, severe cardiomyopathy orventricular arrhythmia requiring medication or mechanical control within 6 months ofapheresis

• History of a seizure disorder, dementia, cerebellar disease or neurodegenerativedisorder

• Known history or prior diagnosis of optic neuritis or other immunologic orinflammatory disease affecting the central nervous system

• Current active liver or biliary disease (except for Gilbert's syndrome orasymptomatic gallstones)

• Evidence of active viral or bacterial infection requiring systemic antimicrobialtherapy, or uncontrolled systemic fungal infection

• Diagnosis of Human herpes virus (HHV) 8-positive DLBCL or T cell/histiocyte-richlarge B-cell lymphoma or Burkitt and high-grade B-cell lymphoma with 11q aberrations (previously Burkitt-like lymphoma) or Richter's transformation or Lymphomatoidgranulomatosis or Plasmablastic lymphoma or Waldenstrom's Macroglobulinemia

• Any prior solid organ or allogeneic stem cell transplantation

• Autologous stem cell transplant within 12 weeks of apheresis; Prior CAR-T celltherapy within 12 weeks of apheresis